Biodexa Pharmaceuticals plc Sponsored ADR BDRX 深 沪
等待开盘 06-26 09:30:00 美东时间
2.50
-0.110
-4.21%
华盛通- 最 高3.1228
- 今 开2.55
- 成交量 8416股
- 最 低 2.4501
- 昨 收 2.61
- 总市值 0
- 52周最高 11.88
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.6005
- 委 比 98.08%
- 总股本 --
- 历史最高 11.88
- 量 比 0.59
- 振 幅 25.77%
- 历史最低 0.0101
- 每 手 1
- 风险率 2.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biodexa Prices $10M Public Offering
Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs,
2025-12-18 21:38
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has named its upcoming Phase 3 study for Familial Adenomatous Polyposis (FAP) as "Serenta." A dedicated website, www.serentatrial.com, has been launched to provide information and resources for patients and healthcare professionals. The study aims to advance eRapa, an oral rapamycin formulation designed to inhibit mTOR and address the challenges associated with current rapamycin treatments.
2025-06-23 12:30
Result of General Meeting
shareholders approved four resolutions. Resolutions 1 and 4 reduce the par value of ordinary shares, while Resolutions 2 and 3 grant the Directors authority to allot ordinary shares non-pre-emptively.
2025-06-11 20:30
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
Biodexa Pharma announced the first patient enrollment in a Phase 2 study of tolimidone for Type 1 Diabetes, conducted by the University of Alberta. Tolimidone aims to improve beta cell function and insulin signaling.
2025-06-04 12:30
Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY
For the year six month period ended June 30 Note2024unaudited£'0002023unaudited£'000Revenue -298Research and development costs (2,189)(2,251)Administrative costs (2,034)(2,291)Loss from
2024-09-26 20:41
Biodexa Pharmaceuticals Announces A Ratio Change On Its ADRs From 1 ADS Representing 400 Ordinary Shares, To The New Ratio Of 1 ADR Representing 10,000 Ordinary Shares (1-For-25) ; Effective Date Of The Ratio Change Is Expected To Be October 4,2024.
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today
2024-09-20 04:33
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
11:12 AM EDT, 09/03/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were falling late Tuesday morning, declining 1.60% to 1,457.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by pharmaceutical company Sanofi (SNY) and se...
2024-09-03 23:12
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Conduit Pharmaceuticals (NASDAQ:CDT) stock increased by 27.4% to $0.16 during Monday's after-market session. The company's market cap stands at $15.0 million. TNF Pharmaceuticals (NASDAQ:TNFA) stock moved upwards by 18.82% to $2.02. The market value of their outstanding shares is at $4.7 mil...
2024-09-03 04:31
